H1N1 provides new universal flu vax hope

Thanks to the H1N1 flu virus, researchers may have found a key to developing a universal flu vaccine. According to a University of Chicago and Emory University study, people infected with H1N1 in 2009 developed antibodies to other flu strains. So, researchers believe that when given the correct immunogen, the body's immune system should stave off multiple flu strains.

"What is really new here is that there was a quantitation of how many of those cross reactive antibodies were made," said Peter Palese, chair of the microbiology department at Mount Sinai School of Medicine, to PBS. "It's very encouraging that people, humans, can make such antibodies in large quantities."

But study author Patrick Wilson still warns that a universal vaccine could be five to 10 years down the road. Still, the research provides valuable information, as the antibodies developed from the 2009 H1N1 strain attack the stalk of the virus, which is generally unchanged in various flu strains.

- see the PBS coverage

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.